Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease

Neuroscience

Volumn 145, Issue 2, 2007, Pages 654-668

  Pattarini, R ^a   Smeyne, R J ^a   Morgan, J I ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

cytokine chemokine; interleukin 6; macrophage inflammatory protein 1; monocyte chemoattractant protein 1; strain differences; tumor necrosis factor

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; C57BL 6 MOUSE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOSE TIME EFFECT RELATION; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION; INFLAMMATION; KNOCKOUT MOUSE; MOLECULAR BIOLOGY; MOUSE STRAIN; NERVE CELL DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STEREOMETRY; STRAIN DIFFERENCE; SUBSTANTIA NIGRA; SWISS WEBSTER MOUSE; ZONA COMPACTA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CELL SURVIVAL; CHEMOKINES; CORPUS STRIATUM; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; RNA, MESSENGER; SPECIES SPECIFICITY; TIME FACTORS;

EID: 33847681800     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.12.030     Document Type: Article

References (152)

1. Adler M.W., Geller E.B., Chen X., and Rogers T.J. Viewing chemokines as a third major system of communication in the brain. AAPS J 7 (2005) E865-E870
2. Allam M.F., Del Castillo A.S., and Navajas R.F. Parkinson's disease risk factors: genetic, environmental, or both?. Neurol Res 27 (2005) 206-208
3. Arakawa Y., Bito H., Furuyashiki T., Tsuji T., Takemoto-Kimura S., Kimura K., Nozaki K., Hashimoto N., and Narumiya S. Control of axon elongation via an SDF-1alpha/Rho/mDia pathway in cultured cerebellar granule neurons. J Cell Biol 161 (2003) 381-391
4. Araki T., Mikami T., Tanji H., Matsubara M., Imai Y., Mizugaki M., and Itoyama Y. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12 (2001) 231-238
5. Bacon K.B., and Harrison J.K. Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. J Neuroimmunol 104 (2000) 92-97
6. Bagri A., Gurney T., He X., Zou Y.R., Littman D.R., Tessier-Lavigne M., and Pleasure S.J. The chemokine SDF1 regulates migration of dentate granule cells. Development 129 (2002) 4249-4260
7. Bajetto A., Bonavia R., Barbero S., and Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 82 (2002) 1311-1329
8. Banisadr G., Fontanges P., Haour F., Kitabgi P., Rostene W., and Melik Parsadaniantz S. Neuroanatomical distribution of CXCR4 in adult rat brain and its localization in cholinergic and dopaminergic neurons. Eur J Neurosci 16 (2002) 1661-1671
9. Banisadr G., Queraud-Lesaux F., Boutterin M.C., Pelaprat D., Zalc B., Rostene W., Haour F., and Parsadaniantz S.M. Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 81 (2002) 257-269
10. Banisadr G., Gosselin R.D., Mechighel P., Kitabgi P., Rostene W., and Parsadaniantz S.M. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: Evidence for its colocalization with neurotransmitters and neuropeptides. J Comp Neurol 489 (2005) 275-292
11. Banisadr G., Gosselin R.D., Mechighel P., Rostene W., Kitabgi P., and Melik Parsadaniantz S. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. J Comp Neurol 492 (2005) 178-192
12. Banisadr G., Rostene W., Kitabgi P., and Parsadaniantz S.M. Chemokines and brain functions. Curr Drug Targets Inflamm Allergy 4 (2005) 387-399
13. Barcia C., Fernandez Barreiro A., Poza M., and Herrero M.T. Parkinson's disease and inflammatory changes. Neurotox Res 5 (2003) 411-418
14. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., and Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 155 (1999) 268-273
15. Bezzi P., Domercq M., Brambilla L., Galli R., Schols D., De Clercq E., Vescovi A., Bagetta G., Kollias G., Meldolesi J., and Volterra A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 4 (2001) 702-710
16. Biber K., de Jong E.K., van Weering H.R., and Boddeke H.W. Chemokines and their receptors in central nervous system disease. Curr Drug Targets 7 (2006) 29-46
17. Boehme S.A., Lio F.M., Maciejewski-Lenoir D., Bacon K.B., and Conlon P.J. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J Immunol 165 (2000) 397-403
18. Bolin L.M., Strycharska-Orczyk I., Murray R., Langston J.W., and Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 83 (2002) 167-175
19. Boven L.A., Montagne L., Nottet H.S., and De Groot C.J. Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin Exp Immunol 122 (2000) 257-263
20. Bradbury A.J., Costall B., Jenner P.G., Kelly M.E., Marsden C.D., and Naylor R.J. MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area. Neuropharmacology 25 (1986) 939-941
21. Brown S.A., Hanscom H.N., Vu H., Brew S.A., and Winkles J.A. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 397 (2006) 297-304
22. Bruno V., Copani A., Besong G., Scoto G., and Nicoletti F. Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloid-induced toxicity in culture. Eur J Pharmacol 399 (2000) 117-121
23. Burns R.S., Markey S.P., Phillips J.M., and Chiueh C.C. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci 11 (1984) 166-168
24. Cardenas H., and Bolin L.M. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice. Brain Res 985 (2003) 89-97
25. Cardona A.E., Pioro E.P., Sasse M.E., Kostenko V., Cardona S.M., Dijkstra I.M., Huang D., Kidd G., Dombrowski S., Dutta R., Lee J.C., Cook D.N., Jung S., Lira S.A., Littman D.R., and Ransohoff R.M. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9 (2006) 917-924
26. Cartier L., Hartley O., Dubois-Dauphin M., and Krause K.H. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 48 (2005) 16-42
27. Carvey P.M., Zhao C.H., Hendey B., Lum H., Trachtenberg J., Desai B.S., Snyder J., Zhu Y.G., and Ling Z.D. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 22 (2005) 1158-1168
28. Chalasani S.H., Sabelko K.A., Sunshine M.J., Littman D.R., and Raper J.A. A chemokine, SDF-1, reduces the effectiveness of multiple axonal repellents and is required for normal axon pathfinding. J Neurosci 23 (2003) 1360-1371
29. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58 (2005) 963-967
30. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003) 1059-1064
31. Chen L.W., Wei L.C., Qiu Y., Liu H.L., Rao Z.R., Ju G., and Chan Y.S. Significant up-regulation of nestin protein in the neostriatum of MPTP-treated mice. Are the striatal astrocytes regionally activated after systemic MPTP administration?. Brain Res 925 (2002) 9-17
32. Chiba K., Trevor A.J., and Castagnoli Jr. N. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128 (1985) 1228-1232
33. Cochiolo J.A., Ehsanian R., and Bruck D.K. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J Neurosci Res 59 (2000) 126-135
34. Cook R., Lu L., Gu J., Williams R.W., and Smeyne R.J. Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice. Brain Res Mol Brain Res 110 (2003) 279-288
35. Cowell R.M., Xu H., Galasso J.M., and Silverstein F.S. Hypoxic-ischemic injury induces macrophage inflammatory protein-1alpha expression in immature rat brain. Stroke 33 (2002) 795-801
36. Desplat-Jego S., Varriale S., Creidy R., Terra R., Bernard D., Khrestchatisky M., Izui S., Chicheportiche Y., and Boucraut J. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 133 (2002) 116-123
37. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 139 (2003) 135-151
38. Eberling J.L., Bankiewicz K.S., Jordan S., VanBrocklin H.F., and Jagust W.J. PET studies of functional compensation in a primate model of Parkinson's disease. Neuroreport 8 (1997) 2727-2733
39. Eugenin E.A., D'Aversa T.G., Lopez L., Calderon T.M., and Berman J.W. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 85 (2003) 1299-1311
40. Faherty C.J., Raviie Shepherd K., Herasimtschuk A., and Smeyne R.J. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res 134 (2005) 170-179
41. Felszeghy K., Banisadr G., Rostene W., Nyakas C., and Haour F. Dexamethasone downregulates chemokine receptor CXCR4 and exerts neuroprotection against hypoxia/ischemia-induced brain injury in neonatal rats. Neuroimmunomodulation 11 (2004) 404-413
42. Felzien L.K., McDonald J.T., Gleason S.M., Berman N.E., and Klein R.M. Increased chemokine gene expression during aging in the murine brain. Brain Res 890 (2001) 137-146
43. Ferger B., Leng A., Mura A., Hengerer B., and Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89 (2004) 822-833
44. Ferger B., Teismann P., Earl C.D., Kuschinsky K., and Oertel W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 360 (1999) 256-261
45. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., and Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97 (2000) 99-112
46. Francis J.W., Von Visger J., Markelonis G.J., and Oh T.H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol Teratol 17 (1995) 7-12
47. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69 (1997) 1322-1325
48. Gao H.M., Liu B., Zhang W., and Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 17 (2003) 1954-1956
49. German D.C., Nelson E.L., Liang C.L., Speciale S.G., Sinton C.M., and Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5 (1996) 299-312
50. Getchell T.V., Subhedar N.K., Shah D.S., Hackley G., Partin J.V., Sen G., and Getchell M.L. Chemokine regulation of macrophage recruitment into the olfactory epithelium following target ablation: involvement of macrophage inflammatory protein-1alpha and monocyte chemoattractant protein-1. J Neurosci Res 70 (2002) 784-793
51. Ghirnikar R.S., Lee Y.L., and Eng L.F. Chemokine antagonist infusion promotes axonal sparing after spinal cord contusion injury in rat. J Neurosci Res 64 (2001) 582-589
52. Gilmour D., Knaut H., Maischein H.M., and Nusslein-Volhard C. Towing of sensory axons by their migrating target cells in vivo. Nat Neurosci 7 (2004) 491-492
53. Greenfield J.G., and Bosanquet F.D. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 16 (1953) 213-226
54. Grunblatt E., Mandel S., and Youdim M.B. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J Neurol 247 Suppl 2 (2000) II95-II102
55. Guyon A., Banisadr G., Rovere C., Cervantes A., Kitabgi P., Melik-Parsadaniantz S., and Nahon J.L. Complex effects of stromal cell-derived factor-1 alpha on melanin-concentrating hormone neuron excitability. Eur J Neurosci 21 (2005) 701-710
56. Guyon A., Skrzydelsi D., Rovere C., Rostene W., Parsadaniantz S.M., and Nahon J.L. Stromal cell-derived factor-1alpha modulation of the excitability of rat substantia nigra dopaminergic neurones: presynaptic mechanisms. J Neurochem 96 (2006) 1540-1550
57. Hakansson A., Westberg L., Nilsson S., Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., and Nissbrandt H. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 133 (2005) 88-92
58. Hamre K., Tharp R., Poon K., Xiong X., and Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828 (1999) 91-103
59. Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., Streit W.J., Salafranca M.N., Adhikari S., Thompson D.A., Botti P., Bacon K.B., and Feng L. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95 (1998) 10896-10901
60. Hassler R. Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48 (1938) 387-476
61. Hatori K., Nagai A., Heisel R., Ryu J.K., and Kim S.U. Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 69 (2002) 418-426
62. Hebert G., Arsaut J., Dantzer R., and Demotes-Mainard J. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 349 (2003) 191-195
63. Hernan M.A., Logroscino G., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 66 (2006) 1097-1099
64. Huerta C., Alvarez V., Mata I.F., Coto E., Ribacoba R., Martinez C., Blazquez M., Guisasola L.M., Salvador C., Lahoz C.H., and Pena J. Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett 370 (2004) 151-154
65. Ishizuka K., Igata-Yi R., Kimura T., Hieshima K., Kukita T., Kin Y., Misumi Y., Yamamoto M., Nomiyama H., Miura R., Takamatsu J., Katsuragi S., and Miyakawa T. Expression and distribution of CC chemokine macrophage inflammatory protein-1 alpha/LD78 in the human brain. Neuroreport 8 (1997) 1215-1218
66. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
67. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 82 (1985) 2173-2177
68. Kaku K., Shikimi T., Kamisaki Y., Shinozuka K., Ishino H., Okunishi H., and Takaori S. Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice. Clin Exp Pharmacol Physiol 26 (1999) 680-683
69. Kalehua A.N., Nagel J.E., Whelchel L.M., Gides J.J., Pyle R.S., Smith R.J., Kusiak J.W., and Taub D.D. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res 297 (2004) 197-211
70. Kim S.H., Kang Y.J., Kim W.J., Woo D.K., Lee Y., Kim D.I., Park Y.B., Kwon B.S., Park J.E., and Lee W.H. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 68 (2004) 396-399
71. Kim Y.D., Sohn N.W., Kang C., and Soh Y. DNA array reveals altered gene expression in response to focal cerebral ischemia. Brain Res Bull 58 (2002) 491-498
72. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., and Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 156 (1999) 50-61
73. Kwong K., Vaishnav R.A., Liu Y., Subhedar N., Stromberg A.J., Getchell M.L., and Getchell T.V. Target ablation-induced regulation of macrophage recruitment into the olfactory epithelium of Mip-1alpha-/- mice and restoration of function by exogenous MIP-1alpha. Physiol Genomics 20 (2004) 73-86
74. Laing K.J., and Secombes C.J. Chemokines. Dev Comp Immunol 28 (2004) 443-460
75. Leng A., Mura A., Feldon J., and Ferger B. Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci Lett 375 (2005) 107-111
76. Li Q., Shirabe K., Thisse C., Thisse B., Okamoto H., Masai I., and Kuwada J.Y. Chemokine signaling guides axons within the retina in zebrafish. J Neurosci 25 (2005) 1711-1717
77. Liberatore G.T., Finkelstein D.I., Wong J.Y., Horne M.K., Porritt M.J., Donnan G.A., and Howells D.W. Sprouting of dopaminergic axons after striatal injury: confirmation by markers not dependent on dopamine metabolism. Exp Neurol 159 (1999) 565-573
78. Lieberam I., Agalliu D., Nagasawa T., Ericson J., and Jessell T.M. A Cxcl12-CXCR4 chemokine signaling pathway defines the initial trajectory of mammalian motor axons. Neuron 47 (2005) 667-679
79. Limatola C., Giovannelli A., Maggi L., Ragozzino D., Castellani L., Ciotti M.T., Vacca F., Mercanti D., Santoni A., and Eusebi F. SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci 12 (2000) 2497-2504
80. Limatola C., Lauro C., Catalano M., Ciotti M.T., Bertollini C., Di Angelantonio S., Ragozzino D., and Eusebi F. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 166 (2005) 19-28
81. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304 (2003) 1-7
82. Liu L., Hsu S.S., Kalia S.K., and Lozano A.M. Injury and strain-dependent dopaminergic neuronal degeneration in the substantia nigra of mice after axotomy or MPTP. Brain Res 994 (2003) 243-252
83. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., and Hong J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 305 (2003) 212-218
84. Lu M., Grove E.A., and Miller R.J. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci U S A 99 (2002) 7090-7095
85. Luo Y., Cai J., Xue H., Miura T., and Rao M.S. Functional SDF1 alpha/CXCR4 signaling in the developing spinal cord. J Neurochem 93 (2005) 452-462
86. Maharaj D.S., Saravanan K.S., Maharaj H., Mohanakumar K.P., and Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44 (2004) 355-360
87. Mandel S., Grunblatt E., and Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J Neural Transm 60 Suppl (2000) 117-124
88. Marchetti B., and Abbracchio M.P. To be or not to be (inflamed): is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol Sci 26 (2005) 517-525
89. Matejuk A., Dwyer J., Ito A., Bruender Z., Vandenbark A.A., and Offner H. Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE. J Neurosci Res 67 (2002) 680-688
90. McGeer E.G., and McGeer P.L. The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 33 (1998) 371-378
91. McGeer P.L., and McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12 Suppl 2 (1998) S1-S6
92. McLaughlin P., Zhou Y., Ma T., Liu J., Zhang W., Hong J.S., Kovacs M., and Zhang J. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53 (2006) 567-582
93. McMahon E.J., Cook D.N., Suzuki K., and Matsushima G.K. Absence of macrophage-inflammatory protein-1alpha delays central nervous system demyelination in the presence of an intact blood-brain barrier. J Immunol 167 (2001) 2964-2971
94. Meighan-Mantha R.L., Hsu D.K., Guo Y., Brown S.A., Feng S.L., Peifley K.A., Alberts G.F., Copeland N.G., Gilbert D.J., Jenkins N.A., Richards C.M., and Winkles J.A. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274 (1999) 33166-33176
95. Meucci O., Fatatis A., Simen A.A., and Miller R.J. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A 97 (2000) 8075-8080
96. Minami M., Katayama T., and Satoh M. Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci 100 (2006) 461-470
97. Mitsumoto Y., Watanabe A., Mori A., and Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Commun 248 (1998) 660-663
98. Mizuno T., Kawanokuchi J., Numata K., and Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 979 (2003) 65-70
99. Muessel M.J., Berman N.E., and Klein R.M. Early and specific expression of monocyte chemoattractant protein-1 in the thalamus induced by cortical injury. Brain Res 870 (2000) 211-221
100. Muessel M.J., Klein R.M., Wilson A.M., and Berman N.E. Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules. Brain Res Mol Brain Res 103 (2002) 12-27
101. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., and Power C.A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52 (2000) 145-176
102. Nagatsu T., Mogi M., Ichinose H., and Togari A. Cytokines in Parkinson's disease. J Neural Transm 58 Suppl (2000) 143-151
103. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 11 (2005) 999-1016
104. Nakayama M., Ishidoh K., Kojima Y., Harada N., Kominami E., Okumura K., and Yagita H. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 170 (2003) 341-348
105. Nishi T., Maier C.M., Hayashi T., Saito A., and Chan P.H. Superoxide dismutase 1 overexpression reduces MCP-1 and MIP-1 alpha expression after transient focal cerebral ischemia. J Cereb Blood Flow Metab 25 (2005) 1312-1324
106. Nishimura M., Kuno S., Mizuta I., Ohta M., Maruyama H., Kaji R., and Kawakami H. Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease. Mov Disord 18 (2003) 953-955
107. Nishimura M., Mizuta I., Mizuta E., Yamasaki S., Ohta M., and Kuno S. Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease. Neurosci Lett 284 (2000) 73-76
108. Nishiyori A., Minami M., Ohtani Y., Takami S., Yamamoto J., Kawaguchi N., Kume T., Akaike A., and Satoh M. Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia?. FEBS Lett 429 (1998) 167-172
109. Novikova L., Garris B.L., Garris D.R., and Lau Y.S. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Neuroscience 140 (2006) 67-76
110. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., and Rinne J.O. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
111. Orr C.F., Rowe D.B., and Halliday G.M. An inflammatory review of Parkinson's disease. Prog Neurobiol 68 (2002) 325-340
112. Parkinson J. An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 14 (1817) 223-236 Reprint of the original article (2002)
113. Perrin F.E., Lacroix S., Aviles-Trigueros M., and David S. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration. Brain 128 (2005) 854-866
114. Poirier J., Kogan S., and Gauthier S. Environment, genetics and idiopathic Parkinson's disease. Can J Neurol Sci 18 (1991) 70-76
115. Potrovita I., Zhang W., Burkly L., Hahm K., Lincecum J., Wang M.Z., Maurer M.H., Rossner M., Schneider A., and Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 24 (2004) 8237-8244
116. Pujol F., Kitabgi P., and Boudin H. The chemokine SDF-1 differentially regulates axonal elongation and branching in hippocampal neurons. J Cell Sci 118 (2005) 1071-1080
117. Ragozzino D., Renzi M., Giovannelli A., and Eusebi F. Stimulation of chemokine CXC receptor 4 induces synaptic depression of evoked parallel fibers inputs onto Purkinje neurons in mouse cerebellum. J Neuroimmunol 127 (2002) 30-36
118. Rinne O.J., Nurmi E., Ruottinen H.M., Bergman J., Eskola O., and Solin O. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 40 (2001) 193-200
119. Robin A.M., Zhang Z.G., Wang L., Zhang R.L., Katakowski M., Zhang L., Wang Y., Zhang C., and Chopp M. Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab 26 (2006) 125-134
120. Ross O.A., O'Neill C., Rea I.M., Lynch T., Gosal D., Wallace A., Curran M.D., Middleton D., and Gibson J.M. Functional promoter region polymorphism of the proinflammatory chemokine IL-8 gene associates with Parkinson's disease in the Irish. Hum Immunol 65 (2004) 340-346
121. Rousselet E., Callebert J., Parain K., Joubert C., Hunot S., Hartmann A., Jacque C., Perez-Diaz F., Cohen-Salmon C., Launay J.M., and Hirsch E.C. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol 177 (2002) 183-192
122. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966 (2003) 245-252
123. Schiess M. Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away?. Arch Neurol 60 (2003) 1043-1044
124. Schulte T., Schols L., Muller T., Woitalla D., Berger K., and Kruger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett 326 (2002) 70-72
125. Schwarting R.K., Sedelis M., Hofele K., Auburger G.W., and Huston J.P. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease. Neurotox Res 1 (1999) 41-56
126. Siebert H., Sachse A., Kuziel W.A., Maeda N., and Bruck W. The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. J Neuroimmunol 110 (2000) 177-185
127. Simpson J.E., Newcombe J., Cuzner M.L., and Woodroofe M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 84 (1998) 238-249
128. Smeyne M., Goloubeva O., and Smeyne R.J. Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia. Glia 34 (2001) 73-80
129. Smeyne M., Jiao Y., Shepherd K.R., and Smeyne R.J. Glia cell number modulates sensitivity to MPTP in mice. Glia 52 (2005) 144-152
130. Song D.D., and Haber S.N. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 20 (2000) 5102-5114
131. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129 (1986) 339-345
132. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16 (2002) 1474-1476
133. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20 (2006) 670-682
134. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 96 (2006) 706-718
135. Stumm R.K., Zhou C., Ara T., Lazarini F., Dubois-Dalcq M., Nagasawa T., Hollt V., and Schulz S. CXCR4 regulates interneuron migration in the developing neocortex. J Neurosci 23 (2003) 5123-5130
136. Takami S., Nishikawa H., Minami M., Nishiyori A., Sato M., Akaike A., and Satoh M. Induction of macrophage inflammatory protein MIP-1alpha mRNA on glial cells after focal cerebral ischemia in the rat. Neurosci Lett 227 (1997) 173-176
137. Tanabe K., Bonilla I., Winkles J.A., and Strittmatter S.M. Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 23 (2003) 9675-9686
138. Tissir F., Wang C.E., and Goffinet A.M. Expression of the chemokine receptor Cxcr4 mRNA during mouse brain development. Brain Res Dev Brain Res 149 (2004) 63-71
139. Trétiakoff C. Contribution a l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques dedutions relatives a la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson. Thesis (1919), University of Paris
140. Tsang F., and Soong T.W. Interactions between environmental and genetic factors in the pathophysiology of Parkinson's disease. IUBMB Life 55 (2003) 323-327
141. Urakami K., Masaki N., Shimoda K., Nishikawa S., and Takahashi K. Increase of striatal dopamine turnover by stress in MPTP-treated mice. Clin Neuropharmacol 11 (1988) 360-368
142. Vilz T.O., Moepps B., Engele J., Molly S., Littman D.R., and Schilling K. The SDF-1/CXCR4 pathway and the development of the cerebellar system. Eur J Neurosci 22 (2005) 1831-1839
143. West M.J., Slomianka L., and Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231 (1991) 482-497
144. Wiley S.R., Cassiano L., Lofton T., Davis-Smith T., Winkles J.A., Lindner V., Liu H., Daniel T.O., Smith C.A., and Fanslow W.C. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15 (2001) 837-846
145. Wilson S.D., Billings P.R., D'Eustachio P., Fournier R.E., Geissler E., Lalley P.A., Burd P.R., Housman D.E., Taylor B.A., and Dorf M.E. Clustering of cytokine genes on mouse chromosome 11. J Exp Med 171 (1990) 1301-1314
146. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 (2002) 1763-1771
147. Xia M.Q., and Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 5 (1999) 32-41
148. Xia M.Q., Qin S.X., Wu L.J., Mackay C.R., and Hyman B.T. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 153 (1998) 31-37
149. Yepes M., Brown S.A., Moore E.G., Smith E.P., Lawrence D.A., and Winkles J.A. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 166 (2005) 511-520
150. Youdim M.B., and Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46 (2004) 1130-1140
151. Zou L.P., Pelidou S.H., Abbas N., Deretzi G., Mix E., Schaltzbeerg M., Winblad B., and Zhu J. Dynamics of production of MIP-1alpha, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 98 (1999) 168-175
152. Zujovic V., Benavides J., Vige X., Carter C., and Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia 29 (2000) 305-315